Pomalidomide and dexamethasone favored prolonged and safe exposure to treatment patients with heavily treated and end-stage relapsed/refractory multiple myeloma, a study published online ahead of print in the journal Annals of Oncology has shown.1
The IFM2009-02 trial evaluated pomalidomide and dexamethasone in very advanced relapsed or refractory multiple myeloma.
The study demonstrated that 40% of patients had prolonged progression-free survival and overall survival. Therefore, researchers sought to analyze the characteristics of these patients and assess the impact of long exposure to pomalidomide on outcomes.
Researchers classified patients into 2 groups: 3 months to less than 1 year, and 1 year or more of treatment with pomalidomide and dexamethasone. Results showed that the overall response rate for the less than 1-year group was 43% compared with 83% for the more than 1-year group, Median progression-free survival was 4.6 months (95% CI, 3.8 – 6.4) and 20.7 months (95% CI, 14.7 – 35.4), respectively.
Median overall survival was 15 months (95% CI, 11.7 – 20.3) with less than 1 year of pomalidomide, while median overall survival had not yet been reached with more than 1 year exposure. The 18-month overall survival rate was 40% and 91%, respectively.
Although regimen optimization of pomalidomide-dexamethasone is warranted in advanced relapsed/refractory multiple myeloma, the authors “believe pomalidomide has proved once more to change the natural history of myeloma in this series, which should be confirmed in a larger study.”
- Fouquet G, Pegourie B, Macro M, et al. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma [published online ahead of print January 19, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw017.